|
|
|
|
|
|
|
|
|
|
|
|
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 18, 2001
Pharmaceutical Formulations, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware (State or Other Jurisdiction of Incorporation) |
0-11274 (Commission File Number) |
22-2367644 (IRS Employer Identification No.) |
460 Plainfield Avenue, Edison, New Jersey 08818
(Address of Principal Executive Offices, including Zip Code)
Registrant's telephone number, including area code: 732-985-7100
N.A.
(Former Name or Former Address, if Changed Since Last Report)
Item 5 Other Events
The Company made the December 15, 2000 interest payments due under its 8% Convertible Subordinated Debentures Due 2002. Such payments were within the time period allowed before such nonpayment would become an event of default under the debenture indenture.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PHARMACEUTICAL FORMULATIONS, INC. By: /s/ R. Bradley Conner Name: R. Bradley Conner Title: Vice President Chief Financial Officer |
Dated: January 18, 2001
|
|